Philips jumps 160 spots on the Forbes 2025 “Canada’s Best Employers” list and gets a top spot in the Healthcare Equipment & Services Category
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the company earned a spot on the Forbes “Canada’s Best Employers 2025” list for the second year in a row. The exclusive ranking is limited to 300 organizations in various industries countrywide, with Philips ranking second in the Healthcare Equipment & Services Category and moving up the list by more than 160 spots from last year.
NEFHSC, Baptist Health & Philips Give Local Families Free Pregnancy+ App
To help ensure more families have access to educational resources they need for healthy birth outcomes, the Northeast Florida Healthy Start Coalition (NEFHSC), Baptist Health and Philips Avent (NYSE: PHG, AEX: PHIA) have partnered to offer a one-year, no-cost subscription to the premium version of Philips’ Pregnancy+. Pregnancy+, the number one pregnancy app worldwide, will be available to women and their families in Baker, Clay and Duval counties.
Philips and icometrix advance precision diagnosis in neurology with innovative AI-based imaging solutions at #RSNA24November 25, 2024icometrix’ FDA-cleared quantitative brain solution for neurological conditions including Alzheimer’s and multiple sclerosis is seamlessly integrated into Philips next generation BlueSeal MR scanners, and will be deployed in its comprehensive informatics platformAmsterdam, the Netherlands and Leuven, Belgium – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and computer-aided diagnostics company icometrix (Leuven, Belgium) have teamed up to deploy an AI-driven, end-to-end solution for acquiring, reading, and reporting the results of MRI brain scans to optimize diagnosis and treatment monitoring of neurological conditions including Alzheimer’s and multiple sclerosis (MS). Unveiled at RSNA 2024, icometrix’s unique AI-powered quantitative reporting software is seamlessly integrated into Philips’ latest BlueSeal MR scanners through Philips’ new Smart Reading capability [1], providing consistent and more accurate diagnosis. The software will also be deployed on Philips’ healthcare informatics platform – including Philips cloud-based AI Manager.The introduction of new drugs that slow the progression of Alzheimer’s emphasizes the critical role of MRI in patient management. By leveraging advanced MRI techniques, neurologists can identify the most suitable candidates for these therapies, ensuring timely and personalized treatment. AI's ability to extract quantitative measurements from brain scans enhances the diagnostic process, enabling quicker decision making and improved monitoring of disease progression. This integration of technology increases efficiency for healthcare providers and leads to more tailored treatment.“Philips is at the forefront of applying AI to help save time and improve diagnostic accuracy so clinicians can deliver better care to more patients,” said Shez Partovi, Chief Innovation & Strategy Officer at Philips. “As these innovations continue to evolve, they hold great promise for transforming the landscape of neurological care, offering hope for better management of chronic conditions like Alzheimer’s and MS. Our partnership with icometrix is an important step forward in the use of AI to help mitigate staff shortages, lower the cost of care, increase diagnostic confidence, and facilitate care orchestration of personalized plans for the growing number of people who are diagnosed with Alzheimer's disease."“Our icobrain imaging AI measures are rapidly becoming the standard of care for diagnosis and monitoring of neurological conditions,” said Wim Van Hecke, CEO of icometrix. “MRI quantification is crucial to unlock precision medicine, especially in the Alzheimer’s disease care pathway, which is why our partnership with Philips is so well timed. We have developed the leading AI solutions for brain MRI monitoring, received CPT III code reimbursement in the US, and we will be able to support radiologists, neurologists, and people with neurological conditions at scale through this collaboration.”Managing the growing volume of Alzheimer’s imaging results Alzheimer’s is the most common form of dementia, accounting for 60% to 70% of the 55 million dementia cases worldwide [2], with more than 150 million people likely to be living with dementia, predominantly Alzheimer’s, by 2050 [3]. With the introduction of monoclonal antibody drugs that break down the amyloid protein deposits in the brain that are believed to be the cause of Alzheimer’s, MRI is now crucial as a part of the diagnostics process as well as to assess treatment effectiveness and help avoid adverse side effects. The latest guidelines for using these drugs involve a minimum of four separate MRI scans during the first year of treatment. High caseloads and the global shortage of neuroradiologists – coupled with the time-consuming nature of manual image reading and difficulty in extracting consistent quantitative measurements – is already putting a severe burden on radiology departments.In addition to icometrix’s icobrain dm software for differential dementia diagnosis, the solution also includes the company’s icobrain ARIA software [4]. The only FDA-cleared solution that is classified as computer-aided detection and diagnosis, Icobrain ARIA can detect and grade the severity of amyloid-related imaging abnormalities. Icobrain ARIA quantifies, in a fully automated way, the extent of a potentially fatal side effect of anti-amyloid drugs known as amyloid-related imaging abnormalities (ARIA) – typically fluid buildup in the brain or blood leakage into brain tissue. Monitoring ARIA over the course of therapy allows neurologists to adjust a patient’s therapy to minimize these side effects. Philips’ latest BlueSeal MR scanners are delivered with standardized AI-based SmartExam planning and AI-accelerated SmartSpeed protocols to image ARIA quickly and easily. Philips unique Smart Reading software [4] also allows end-to-end seamless integration of imaging protocols with the icometrix icobrain ARIA software to deliver fast, fully automated, quantitative outcomes for Alzheimer’s patients. Integrated into Philips’ healthcare informatics platform, these breakthrough AI-driven diagnostic and therapy monitoring capabilities fit seamlessly into radiology MR workflows and hospital PACS.Speeding the differential diagnosis of multiple sclerosisTo ensure more confident diagnosis of MS, new clinical guidelines have been introduced that include a special MR imaging protocol and FLAIR* generation in Philips Advanced Visualization Workspace to simultaneously create high-quality images of white matter lesions and veins. Philips is currently the only commercial supplier of MR scanners that can perform FLAIR* imaging. icometrix icobrain ms, also seamlessly integrates on the Philips MR scanner and Philips AI Manager. It counts the number of white-matter lesions forming around veins – a characteristic highly specific to MS and it also allows for longitudinal and quantitative comparison of follow-up MRI exams, which are essential for treatment decision-making.Philips’ latest neuroimaging solutions and icometrix’s software solutions for Alzheimer’s and MS will be available on the Philips BlueSeal 1.5T MR scanners and Philips’ 3.0T MR portfolio. The solutions will be demonstrated in the Philips booth (6730) and the icometrix booth (4903) at the Radiological Society of North America Annual Meeting (RSNA 2024, December 1-4, Chicago, USA). For more information, visit Philips at RSNA 2024.[1] BlueSeal XE/SE and Smart Reading is not yet CE marked, not cleared in all countries, and not yet available for delivery in any country. Please consult your Philips contact person for further information.[2] World Health Organization (WHO), Dementia Key Facts https://www.who.int/news-room/fact-sheets/detail/dementia[3] Nichols, Emma et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. The Lancet Public Health, Volume 7, Issue 2, e105 - e125 https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(21)00249-8/fulltext[4] Philips and Icometrix have the intention to make icobrain aria software available for reselling in the USA through the Philips catalog, as well as a Smart Reading solution on MR platforms. Philips AI Manager is not intended for data interpretation or diagnosis. Availability of 3rd party algorithm may vary per market. The functionalities and benefits of the solution depend on customer-specific configuration and use. Please contact your local Philips representative for market availability.
Philips enrolls first patient in U.S. clinical trial for innovative integrated single-device to treat peripheral artery diseaseAmsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced enrollment of the first patient in the U.S. THOR IDE clinical trial, which will study an innovative combined laser atherectomy and intravascular lithotripsy catheter developed by Philips, that integrates two critical PAD treatments into a single device. Procedures that previously required the use of two different devices can now be performed in a single procedure using a single device, simplifying workflows and procedures and potentially reducing the risk and improving outcomes for patients who might otherwise face multiple complex interventions.
Philips to Further Roll Out RATE: AI for Early Infection Detection at U.S. Department of Defense Through Four-Year, $25 Million Contract
Royal Philips (NYSE: PHG, AEX: PHIA) today announced it will accelerate the predictive health monitoring of the Rapid Analysis of Threat Exposure (RATE) algorithm to support the well-being and readiness of active-duty service personnel for the U.S. Department of Defense (DoD). Over the next four years, the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), will invest $25 million to make the technology more accessible in the field.
Jackson Health System projects 47% reduction in carbon emissions from patient monitors with Philips next generation monitoring platformOpportunity for significant savings in energy consumption, reduction of paper and elimination of disposable batteries for telemetry revealed in Life Cycle Assessment
Philips announces FDA approval for enhanced LumiGuide guidewire and marks the 1000th patient treated with its breakthrough 3D device guidance technologyAmsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the introduction of the 160cm FDA approved version of its unique LumiGuide endovascular navigation wire. This enhanced LumiGuide guidewire, which utilizes the company’s breakthrough Fiber Optic RealShape (FORS) technology, was used for the first time on a patient by Professor and vascular surgeon Carlos Timaran, MD, an internationally recognized expert in advanced endovascular techniques. He used the technology during a complex aortic aneurism repair operation, marking the 1000th patient treated milestone using FORS technology since first clinical use of the technology in 2020. The introduction of a longer FORS-enabled LumiGuide Navigation Wire enables US clinicians to visualize a broader range of catheters and expands usage of this technology to patients in America treated in centers equipped with LumiGuide.
Carilion Clinic Further Expands Quality Cardiac Care Access with Latest Philips Innovations at Region’s Premier Cardiovascular Institute at Crystal Spring Tower in Virginia
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Carilion Clinic, a not-for-profit health care organization serving more than one million people in Virginia and West Virginia, today announced Carilion will adopt the Philips cardiovascular care ecosystem of solutions at the future home of its Cardiovascular Institute at Crystal Spring Tower. Carilion will have 11 specialized Philips interventional suites, allowing physicians to treat patients with complex cardiovascular conditions closer to home while optimizing the clinical, operational and overall performance of the health system’s cardiovascular service line. This investment illustrates Carilion’s commitment to empowering its clinicians with innovative technology to provide quality care for its communities.
88% of US Healthcare Leaders say the use of automation for repetitive tasks is critical for addressing staff shortages in new Philips Future Health Index
The Future Health Index (FHI) survey conducted by Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, explores the ongoing staffing and access challenges within the US healthcare system and the innovative solutions being used to address them. The ninth annual report, Better care for more people, demonstrates the pressures of staffing shortages and burnout on clinicians and their ability to deliver timely, high-quality care to patients. It reveals how healthcare leaders are investing in technologies such as automation and artificial intelligence to help ease the burden on staff, and those that are having an impact on increasing access and health equity such as virtual care.
Philips completes cancellation of 15.1 million sharesDecember 19, 2023Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA) today announced that it has completed the cancellation of 15,134,054 of its shares. The cancelled shares were acquired as part of the EUR 1.5 billion share repurchase program for capital reduction purposes that was announced on July 26, 2021. Philips will complete the share repurchase program in April 2024, which is expected to result in a further cancellation of 4.4 million shares in Q2 2024. Philips’ current issued share capital amounts to EUR 182,703,193 representing 913,515,966 common shares.
Michigan Department of Health and Human Services Expands Philips Avent Pregnancy+ Program; Nearly 80% of Users Say App Has Helped Them Learn More About Locally Available Maternal Health Resources
Medicaid-eligible Michigan families will now be able to access new and premium content in the Philips Avent Pregnancy+ mobile app, as the Michigan Department of Health and Human Services (MDHHS) has extended its contract with Royal Philips, (NYSE: PHG, AEX: PHIA) a global leader in health technology.
Philips Earns High Score for Fifth Time in Human Rights Campaign Foundation’s 2023-2024 Corporate Equality Index
Royal Philips (NYSE: PHG, AEX: PHIA) a global leader in health technology, has received a score of 90 out of 100 on the Human Rights Campaign Foundation’s 2023-2024 Corporate Equality Index (CEI), the nation’s foremost benchmarking survey and report measuring corporate policies and practices related to LGBTQ+ workplace equality. Philips joins 1,384 major U.S. businesses that were also ranked in the 2023-2024 CEI.
Philips ranks #1 in ‘Health Care Equipment & Services’ sector on Forbes’ 2023 ‘World’s Best Employers’ List
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that once again, the company earned a spot on Forbes’ 2023 “World’s Best Employers” list. Philips has appeared within the top 100 for the past four years, and holds this position among the 700 organizations around the globe that were included in the 2023 list. Philips’ ranking identifies the company as the best employer in the world in the Health Care Equipment & Services category.
